Research programme: anticancer therapeutics and diagnostics - Biosceptre International

Drug Profile

Research programme: anticancer therapeutics and diagnostics - Biosceptre International

Alternative Names: BIL-03s; BIL-221s

Latest Information Update: 19 Dec 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Arana Therapeutics; Biosceptre International
  • Developer Biosceptre International
  • Class Antibodies; Diagnostic agents; Imaging agents; Monoclonal antibodies
  • Mechanism of Action Purinergic P2X7 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 14 Dec 2017 Preclinical development in Cancer is ongoing in Australia (Parenteral)
  • 14 Dec 2017 Biosceptre plans a phase I trial for of BIL 03s for Cancer in Australia
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Australia (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top